Big Pharma race to snap up biotech assets as $170 billion patent cliff looms

Large pharmaceutical companies are aggressively acquiring biotechnology firms as they face a significant 'patent cliff' starting in 2029, which threatens to wipe out an estimated $170 billion in revenue for blockbuster drugs. This M&A rush is driven by the need to replenish pipelines with innovative, patented drugs to offset the financial impact of expiring patents and maintain growth. The development arrives against a backdrop of shifting risk appetite, where investors are reassessing exposure to markets and weighing the second-order impact on adjacent sectors. Investors are watching the broader tape for follow-through. Live pricing was not available at the time of writing, but positioning data and order-book signals will shape the next session. Positioning across funds, options skew and credit spreads typically respond first; equity price action lags but tends to confirm the direction once volume returns. Readers should treat the immediate move as a sentiment proxy rather than a final verdict on fundamentals. For longer-horizon allocators the more important question is whether this changes the trajectory of cash flows, regulation or competitive dynamics. If it does, multiple compression or expansion follows; if it does not, the reaction fades within a few sessions and the prior trend reasserts itself. What to watch next: forthcoming earnings prints, central-bank guidance and any official commentary that either validates or pushes back on the market's interpretation. Reported by CNBC and contextualised by the Global Investing News desk under Mark Grundell.